Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia
G Pichert, D C Roy, R Gonin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 1992
Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors
G Pichert, J Peters, R A Stahel, et al.
Clinical Lymphoma
|
November 15, 2001
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
G Pichert, S F Schmitz, U Hess, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2000
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini, S F Schmitz, K Bürki, et al.
Familial Cancer
|
March 20, 2010
Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers
G Pichert, C Jacobs, I Jacobs, et al.
British Journal of Haematology
|
April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission
R A Stahel, L M Jost, T Kroner, et al.
Journal of Medical Genetics
|
April 17, 2008
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
A C Antoniou, R Hardy, L Walker, et al.
Journal of Medical Genetics
|
November 11, 2008
Risk reducing mastectomy: outcomes in 10 European centres
D G R Evans, A D Baildam, E Anderson, et al.
British Journal of Cancer
|
August 27, 2009
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
O M Sinilnikova, A C Antoniou, J Simard, et al.
British Journal of Cancer
|
November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
A Osorio, R L Milne, G Pita, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia
G Pichert, D C Roy, R Gonin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 1992
Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors
G Pichert, J Peters, R A Stahel, et al.
Clinical Lymphoma
|
November 15, 2001
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
G Pichert, S F Schmitz, U Hess, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2000
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini, S F Schmitz, K Bürki, et al.
Familial Cancer
|
March 20, 2010
Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers
G Pichert, C Jacobs, I Jacobs, et al.
British Journal of Haematology
|
April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission
R A Stahel, L M Jost, T Kroner, et al.
Journal of Medical Genetics
|
April 17, 2008
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
A C Antoniou, R Hardy, L Walker, et al.
Journal of Medical Genetics
|
November 11, 2008
Risk reducing mastectomy: outcomes in 10 European centres
D G R Evans, A D Baildam, E Anderson, et al.
British Journal of Cancer
|
August 27, 2009
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
O M Sinilnikova, A C Antoniou, J Simard, et al.
British Journal of Cancer
|
November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
A Osorio, R L Milne, G Pita, et al.
Page
of 3